Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in acute bipolar depression
NCT05867849Phase 3Recruiting
- Sponsor
- University of British Columbia
- Start
- Oct 2023
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Cannabidiol Arm with Placebo Arm (2 arms). Primary endpoint: Improvement in depressive symptoms measured by MADRS at 6 weeks. Started Oct 2023; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT05867849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867849.